昭衍新藥(06127.HK)參投長春百克生物科技A股IPO
昭衍新藥(06127.HK)公布,以自有資金參與長春百克生物科技股份公司A股IPO的戰略投資者配售,公司擬獲配120萬股,發行價格為每股36.35元人民幣,獲配金額為4,383.81萬元人民幣,所獲配股票鎖定期為12個月。
公司表示,與百克生物已保持多年緊密的合作關系,此次參與戰略配售有利於繼續深化雙方業務合作,雙方擬就傳染病防治的生物藥物(含疫苗)研發、中試、生產、非臨床評價、臨床服務(包括臨床註冊、臨床運營、臨床檢測、中心實驗室、藥物警戒)等領域積極開展戰略合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.